Early Palliative Care in Non–Small-Cell Lung Cancer
Authors:
- Eiki IchiharaEIEiki Ichihara
- Junji MatsuokaJMJunji Matsuoka
- Katsuyuki KiuraKKKatsuyuki Kiura
- 2 December 2010
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (23) , 2263-2265
Abstract
The surprising and encouraging study by Temel and colleagues (Aug. 19 issue)1 suggests that the early introduction of palliative care prolongs survival among patients with metastatic non-small-cell lung cancer. However, two essential points regarding patient demographic characteristics were not reported. First, there were no data regarding the regimens and number of chemotherapy cycles in each group. Could the patients assigned to early palliative care undergo more chemotherapy? Second, the authors did not describe whether the patients assigned to early palliative care, as compared with the patients assigned to standard care, had better performance status after intervention. The use of chemotherapy and performance status are inextricably linked with survival in metastatic non–small-cell lung cancer.2,3 We would like to know whether the early palliative care itself resulted in longer survival through improvements in the quality of life and mood or whether the better performance status restored with early palliative care made it possible to receive additional chemotherapy at an appropriate time that might confer a survival benefit.Keywords
This publication has 10 references indexed in Scilit:
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLCJournal of Thoracic Oncology, 2010
- Nurse and physician inter-rater agreement of three performance status measures in palliative care outpatientsSupportive Care in Cancer, 2009
- Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group TrialsJournal of Clinical Oncology, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire?Results from Eastern Cooperative Oncology Group (ECOG) Study 5592Journal of Clinical Epidemiology, 2002
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987